Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLS006
MIFTS: 40

Plasmodium Vivax Malaria

Categories: Infectious diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Plasmodium Vivax Malaria

About this section

MalaCards integrated aliases for Plasmodium Vivax Malaria:

Name: Plasmodium Vivax Malaria 11 14 16 31
Malaria, Vivax 43 71
Malaria by Plasmodium Vivax 11
Vivax Malaria 11
Malaria Vivax 53

Classifications:

MalaCards categories:
Global: Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 31
ICD11: 33


External Ids:

Disease Ontology 11 DOID:12978
ICD9CM 34 084.1
MeSH 43 D016780
NCIt 49 C34800
SNOMED-CT 68 27052006
UMLS 71 C0024537
Sources

Summaries for Plasmodium Vivax Malaria

About this section

Disease Ontology: 11 A malaria that is caused by the protozoan parasite Plasmodium vivax, which induces paroxysms at 48-hour intervals.

MalaCards based summary: Plasmodium Vivax Malaria, also known as malaria, vivax, is related to plasmodium falciparum malaria and bilirubin metabolic disorder. An important gene associated with Plasmodium Vivax Malaria is G6PD (Glucose-6-Phosphate Dehydrogenase). The drugs Piperaquine and Lumefantrine have been mentioned in the context of this disorder. Affiliated tissues include spleen, liver and t cells, and related phenotypes are homeostasis/metabolism and hematopoietic system
Sources

Related Diseases for Plasmodium Vivax Malaria

About this section

Diseases related to Plasmodium Vivax Malaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 329)
# Related Disease Score Top Affiliating Genes
1 plasmodium falciparum malaria 31.5 TNF IL10 G6PD DHPS DHFR
2 bilirubin metabolic disorder 30.8 TNF IL10 G6PD CYP2D6
3 iron metabolism disease 30.7 TFRC MT-CYB G6PD
4 dengue disease 30.7 TNF SERPINA3 IL10
5 viral infectious disease 30.6 TNF SERPINA3 IL10 ACKR1
6 plasmodium ovale malaria 30.5 MT-CYB KLHL2 G6PD CYP2D6
7 plasmodium malariae malaria 30.3 MT-CYB DNAJC5 DHFR
8 spinal cord disease 30.3 TNF SERPINA3 IL10
9 mixed malaria 30.3 SALL1 MT-CYB KLHL2 ACKR1
10 anemia, autoimmune hemolytic 30.3 IL10 GYPA G6PD
11 herpes zoster 30.2 IL10 GYPC DHFR
12 pneumonia 30.2 TNF IL10 DHPS DHFR
13 blood platelet disease 30.2 TNF SERPINA3 IL10 GATA1
14 chickenpox 30.1 TNF IL10 GYPC
15 babesiosis 30.1 TNF MT-CYB IL10
16 hemolytic anemia 30.0 TFRC HBE1 GYPA GATA1 G6PD
17 visceral leishmaniasis 30.0 TNF MT-CYB IL10
18 aplastic anemia 30.0 TNF TFRC IL10 GATA1
19 glucosephosphate dehydrogenase deficiency 29.9 TNF HBE1 GYPA G6PD FYB1 CYP2D6
20 deficiency anemia 29.8 TNF TFRC SERPINA3 IL10 HBE1 GYPA
21 toxoplasmosis 29.8 TNF IL10 G6PD DHPS DHFR
22 thalassemia 29.8 TFRC HBE1 GATA1 G6PD
23 malaria 29.5 TNF TFRC SERPINA3 MT-CYB IL10 HBE1
24 leukemia, acute myeloid 29.5 TNF TFRC SERPINA3 IL10 GYPA GATA1
25 congenital hemolytic anemia 29.4 TFRC HBE1 GYPA GATA1 G6PD
26 hereditary elliptocytosis 29.3 HBE1 GYPC GYPA G6PD ACKR1
27 hemoglobinopathy 29.1 TFRC SERPINA3 HBE1 GYPA GATA1 G6PD
28 sickle cell anemia 28.8 TNF TFRC HBE1 GYPA GATA1 G6PD
29 hereditary spherocytosis 28.7 TFRC HBE1 GYPC GYPA GATA1 G6PD
30 thrombocytopenia 10.9
31 adult respiratory distress syndrome 10.9
32 acute kidney failure 10.7
33 splenomegaly 10.7
34 hypoglycemia 10.6
35 tatton-brown-rahman syndrome 10.6
36 disseminated intravascular coagulation 10.6
37 cytokine deficiency 10.6
38 exanthem 10.5
39 hemophagocytic lymphohistiocytosis, familial, 1 10.5
40 rhabdomyosarcoma 2 10.5
41 pancytopenia 10.5
42 nutritional deficiency disease 10.5
43 kidney disease 10.5
44 myocarditis 10.5
45 hemolytic uremic syndrome, atypical 1 10.4
46 pulmonary edema 10.4
47 hemolytic-uremic syndrome 10.4
48 cholestasis 10.4
49 splenic infarction 10.4
50 acute disseminated encephalomyelitis 10.4

Graphical network of the top 20 diseases related to Plasmodium Vivax Malaria:



Diseases related to Plasmodium Vivax Malaria
Sources

Symptoms & Phenotypes for Plasmodium Vivax Malaria

About this section

MGI Mouse Phenotypes related to Plasmodium Vivax Malaria:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.8 ACKR1 AKR1C2 DHFR DHPS DNAJC5 FYB1
2 hematopoietic system MP:0005397 9.4 DHFR DHPS FYB1 G6PD GATA1 GYPA
Sources

Drugs & Therapeutics for Plasmodium Vivax Malaria

About this section

Drugs for Plasmodium Vivax Malaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Piperaquine Approved, Experimental, Investigational Phase 4 4085-31-8
2
Lumefantrine Approved Phase 4 82186-77-4 6437380
3
Tafenoquine Approved, Investigational Phase 4 106635-80-7 115358
4
Mefloquine Approved, Investigational Phase 4 53230-10-7 4046
5
Primaquine Approved Phase 4 90-34-6 4908
6
Artesunate Approved, Investigational Phase 4 88495-63-0 6917864 5464098
7
Artemether Approved Phase 4 71963-77-4 68911 9796294
8
Lactitol Approved, Investigational Phase 4 585-86-4 157355
9 Liver Extracts Phase 4
10 Artemether, Lumefantrine Drug Combination Phase 4
11 Antiviral Agents Phase 4
12 Anthelmintics Phase 4
13 Anti-Inflammatory Agents, Non-Steroidal Phase 4
14 Anti-Inflammatory Agents Phase 4
15 Artemisinins Phase 4
16 Analgesics, Non-Narcotic Phase 4
17 Analgesics Phase 4
18
Artenimol Approved, Experimental, Investigational Phase 3 71939-50-9 540327
19
Amodiaquine Approved, Investigational Phase 3 86-42-0 2165
20 Orange Approved Phase 3
21
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0, 19085-09-7 4993
22
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
23
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
24
Dapsone Approved, Investigational Phase 3 80-08-0 2955
25
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
26
Chlorproguanil Investigational Phase 3 537-21-3 22323 9571037
27
Pyronaridine Investigational Phase 3 74847-35-1 5485198
28 Anti-Bacterial Agents Phase 3
29 Folic Acid Antagonists Phase 3
30 Folate Phase 3
31 Vitamin B9 Phase 3
32 Vitamin B Complex Phase 3
33 Fanasil, pyrimethamine drug combination Phase 3
34
Cobicistat Approved Phase 2 1004316-88-4 24950485 25151504
35
Tinidazole Approved, Investigational Phase 2 19387-91-8 5479
36
Artefenomel Investigational Phase 2 1029939-86-3 24999143
37 Alkylating Agents Phase 2
38 Vaccines Phase 2
39 Immunologic Factors Phase 2
40 Adjuvants, Immunologic Phase 2
41 Monatide (IMS 3015) Phase 2
42
Moxifloxacin Approved, Investigational Phase 1 186826-86-8, 354812-41-2, 151096-09-2 152946
43
Sorbitol Approved, Investigational Phase 1 69-65-8, 50-70-4 453 6251 5780
44 Norgestimate, ethinyl estradiol drug combination Phase 1
45 Pharmaceutical Solutions Phase 1
46 Freund's Adjuvant Phase 1
47 diuretics Phase 1
48
Permethrin Approved, Investigational 52645-53-1 40326
49
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
50
Tannic acid Approved 1401-55-4 16129878 16129778

Interventional clinical trials:

(show top 50) (show all 91)
# Name Status NCT ID Phase Drugs
1 An Open Label Randomized Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand Unknown status NCT01662700 Phase 4 Artesunate;Chloroquine
2 A Randomised Controlled Trial to Assess the Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam Completed NCT01887821 Phase 4 Chloroquine;Dihydroartemisinin/Piperaquine
3 Assessing Chloroquine Resistance of Plasmodium Vivax in Malaria Endemic Area Completed NCT02118090 Phase 4 Chloroquine sulfate;DHA-PP
4 Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas - a Randomized Controlled Trial Completed NCT03916003 Phase 4 primaquine
5 G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria Completed NCT02876549 Phase 4 Chloroquine;Primaquine 0.25 mg/kg/day;Primaquine 0.75 mg/kg weekly
6 Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan Completed NCT01178021 Phase 4 Chloroquine;Chloroquine/Primaquine
7 Short Course Radical Cure of P.Vivax in Nepal- a Randomized Controlled Trial Recruiting NCT04079621 Phase 4 primaquine
8 Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure Recruiting NCT04706130 Phase 4 Primaquine;Artesunate
9 Optimizing the Dose of Tafenoquine for the Radical Cure of Plasmodium Vivax Malaria in Southeast Asia Not yet recruiting NCT04704999 Phase 4 Tafenoquine;Chloroquine;Artemether 20 mg-Lumefantrine 120 mg
10 A Multi-center, Open-label, Randomized Trial of Chloroquine, Artemether-Lumefantrine, and Mefloquine-Artesunate for the Treatment of Uncomplicated P. Vivax Malaria in Pregnant Women in Brazil Terminated NCT01107145 Phase 4 Mefloquine- Artesunate;Artemether-Lumefantrine;Chloroquine
11 Developing a Methodology to Assess 8-aminoquinoline Associated Haemolytic Risk in Females Heterozygous for G6PD in Endemic Populations Terminated NCT03337152 Phase 4 primaquine;chloroquine + primaquine
12 Prevention of P. Vivax Malaria During Pregnancy: Effects on Mother and Child Health in Santa Cruz, Bolivia. Open, Multicentric, Randomized Clinical Trial, Comparing Prophylaxis Once a Week to Malaria Attack Treatment, Both by Chloroquine. Withdrawn NCT00290420 Phase 4 Chloroquine profilaxis
13 Artemether-lumefantrine vs Chloroquine in Patients With Acute Non-severe P. Vivax Malaria in Sabah, Malaysia Unknown status NCT02348788 Phase 3 Artemether-lumefantrine + Primaquine;Chloroquine + Primaquine
14 Study 200894: A Double-blind, Double-dummy, Randomized, Parallel Group, Placebo-controlled Superiority Study to Evaluate the Efficacy and Safety of Tafenoquine (SB-252263, WR238605) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax Malaria Completed NCT02802501 Phase 3 Tafenoquine;Matched-Placebo for Tafenoquine;Primaquine;Matched-Placebo for Primaquine;Dihydroartemisinin-piperaquine (DHA-PQP);ACT plus PQ (Rescue medication);PQ (End of study treatment)
15 Artemether/Lumefantrine in the Treatment of Plasmodium Vivax Malaria in Eastern Sudan Completed NCT01625871 Phase 3 tablets artemether/lumefantrine
16 Comparison of the Efficacy and Safety of Two ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria in North Sumatera, Indonesia: 1 Year Followup Completed NCT01288820 Phase 3 Dihydroartemisinin/piperaquine + primaquine;Artesunate-amodiaquine + primaquine
17 A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in the Treatment of Subjects With Plasmodium Vivax Malaria Completed NCT02216123 Phase 3 Tafenoquine;Tafenoquine Placebo;Chloroquine;Primaquine;Primaquine Placebo
18 Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine (PQ) for the Treatment of Uncomplicated Plasmodium Vivax Infection Completed NCT02691910 Phase 2, Phase 3 Chloroquine;Primaquine
19 A Phase III Comparative (Double-blind, Double-dummy) Randomised Multicentre Study to Assess the Safety & Efficacy of Oral Pyronaridine Artesunate (180:60 mg) Versus Chloroquine (155 mg) in Children & Adult Patients With Acute Vivax Malaria Completed NCT00440999 Phase 3 Pyronaridine artesunate;Chloroquine
20 Randomized Clinical Trial of the Efficacy and Safety of Dihydroartimisinine+Papiraquine (Artekin) Compared With First Line Drugs for Treatment of Vivax and Uncomplicated Falciparum Malaria in Afghanistan Completed NCT00682578 Phase 3 Dihydroartemisinin + Piperaquine (Artekin);artesunate-sulphadoxin/pyrimethamine, chloroquine
21 A Placebo Controlled, Randomised Evaluation of an Eight Week Primaquine Regimen for the Treatment of Vivax Malaria. Completed NCT00158587 Phase 3 primaquine
22 An Open-label Three Arm Trial of the Efficacy and Safety of Chlorproguanil / Dapsone (Lapdap) Compared With Chloroquine and Sulfadoxine / Pyrimethamine for the Treatment of Vivax Malaria in Pakistan and Afghanistan Completed NCT00158561 Phase 3 sulfadoxine-pyrimethamine and chlorproguanil-dapsone
23 Studies on Adding Artesunate to Existing Antimalarial Therapies With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan Completed NCT00158548 Phase 3 SP, chloroquine, amodiaquine, primaquine, artesunate
24 Randomised Parallel Open Label Comparison Between 7 and 14 Day Primaquine Combined With 3-day Dihydroartemisinin-piperaquine or 3-day Chloroquine Regimens for Radical Cure of Plasmodium Vivax Completed NCT01640574 Phase 3 Dihydroartemisinin-Piperaquine;Chloroquine
25 A Randomised Open Label Study Comparing the Efficacy of Chloroquine/Primaquine, Chloroquine and Artesunate in the Treatment of Vivax Malaria Along the Thai-Burmese Border Completed NCT01074905 Phase 3 Artesunate;Chloroquine;Chloroquine/Primaquine
26 Artesunate-mefloquine vs Chloroquine in Patients With Acute Uncomplicated P. Knowlesi and P. Vivax Malaria: a Randomized Open Label Trial in Sabah, Malaysia Completed NCT01708876 Phase 3 Artesunate-mefloquine;Chloroquine;Primaquine
27 Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine - a Randomized Controlled Trial in P. Vivax Patients Recruiting NCT04411836 Phase 3 Tafenoquine;Primaquine
28 An Open Label Randomized Comparative Study to Assess the Efficacy and Tolerability of Eurartesim® Versus Chloroquine and Nonrelapse Therapy With Primaquine for Uncomplicated Plasmodium Vivax Monoinfection Malaria Active, not recruiting NCT03208907 Phase 3 CQ coadministered with PQ;DHA-PQP coadministered with PQ;CQ and PQ starting on Day 42;DHA-PQP and PQ starting on Day 42
29 Primaquine Double Dose for Radical Cure of Plasmodium Vivax in Colombia Not yet recruiting NCT05232227 Phase 2, Phase 3 Primaquine double dose over 14 days;Primaquine single dose over 14 days
30 A Phase III Randomised, Double-blind, Double-dummy, Comparative Study to Assess the Safety and Efficacy of Pyronaridine Artesunate (180:60 mg) Versus Chloroquine (155 mg) in Children and Adult Patients in Korea With Acute P. Vivax Malaria Terminated NCT04368910 Phase 3 Pyronaridine - artesunate;Chloroquine
31 A Proof-of-Concept, Open Label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Single Doses of DSM265 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-Infection Over a 35-Day-Extended Observation Period Completed NCT02123290 Phase 2 DSM265 400mg;DSM265 xmg;DSM265 ymg
32 An Open Label, Non-comparative, Multicenter Study to Assess the Pharmacokinetics, Safety and Efficacy of Tafenoquine (SB-252263, WR238605) in the Treatment of Pediatric Subjects With Plasmodium Vivax Malaria Completed NCT02563496 Phase 2 Tafenoquine;Chloroquine
33 A Phase IIa Challenge Study to Assess Efficacy of the Plasmodium Vivax Malaria Vaccine Candidates ChAd63 PvDBP and MVA PvDBP in Healthy Adults Living in the UK Completed NCT04009096 Phase 2
34 A Multi-centre, Double-blind, Randomised, Parallel-group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tafenoquine (SB-252263, WR238605) in Subjects With Plasmodium Vivax Malaria. Completed NCT01376167 Phase 2 Chloroquine 600mg;Chloroquine 300mg;Tafenoquine 50mg;Tafenoquine 100mg;Tafenoquine 300mg;Tafenoquine 600mg;Primaquine 15mg;Chloroquine 600mg (Part 2 );Chloroquine 300mg (Part 2 );Tafenoquine 300mg (Part 2);Primaquine 15mg (Part2 )
35 Phase 1/2a Open-label Dose Safety, Reactogenicity, Immunogenicity and Efficacy of the Candidate Plasmodium Vivax Malaria Protein 001 (VMP001) Administered Intramuscularly With GlaxoSmithKline (GSK) Biologicals' Adjuvant System AS01B in Healthy Malaria-Naïve Adults Completed NCT01157897 Phase 1, Phase 2
36 An Open Label Phase 2a Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of (+)-SJ000557733 (SJ733) With or Without Cobicistat in Adult Patients With Acute, Uncomplicated Malaria Over a 42 Day Period Completed NCT04709692 Phase 2 (+)-SJ000557733 (SJ733)
37 Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax Completed NCT00811096 Phase 2 Tinidazole;chloroquine
38 A Randomised Non-Inferiority Trial of Sulfadoxine-Pyrimethamine Plus Artesunate Compared to Chloroquine for the Treatment of Vivax Malaria in Eastern Afghanistan. Completed NCT00486694 Phase 2 Sulfadoxine-pyrimethamine + artesunate;Chloroquine
39 Phase IIa Exploratory, Open Label, Single/Multiple Dose Testing Clinical Study to Assess the Preliminary Efficacy, Tolerability and PK of OZ439 in Adult Patients With Acute, Uncomplicated P. Falciparum or Vivax Malaria Mono-infection Completed NCT01213966 Phase 2 OZ439
40 A Proof-of-concept, Open Label, 3-day Repeated Dose Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection Completed NCT01524341 Phase 2 KAE609
41 A Proof-of-concept, Open Label Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection Completed NCT01753323 Phase 2 KAF156
42 Phase IIB Study to Evaluate Primaquine Safety and Tolerability for Radical Cure of Uncomplicated Plasmodium Vivax Malaria in Children < 15 Years-old (CHILDPRIM) Recruiting NCT05044637 Phase 2 Primaquine
43 A Phase I/IIa Clinical Trial to Assess the Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1 in Healthy Adults Living in the UK Recruiting NCT04201431 Phase 1, Phase 2
44 Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in Glucose 6-phosphate Dehydrogenase Deficient Patients Recruiting NCT03529396 Phase 2 Chloroquine;Primaquine
45 A Phase II Clinical Study to Assess the Safety, Immunogenicity, and Efficacy of Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvRII/Matrix-M in Healthy Thai Adults Living in Thailand Not yet recruiting NCT05380388 Phase 2
46 Safety and Protective Efficacy of a Synthetic Vaccine Derived From the CS Protein of Plasmodium Vivax: a Double-blind, Placebo-controlled, Randomized Clinical Trial in naïve and Pre-immune Colombian Volunteers Not yet recruiting NCT04739917 Phase 2
47 Proof of Concept Study of Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria Terminated NCT02110784 Phase 2 Eurartesim tablets
48 Feasibility of Methylene Blue-based Combination Therapy in the Radical Treatment of Adult Patients With Plasmodium Vivax Malaria in Ethiopia: a Randomised Controlled Pilot Trial Withdrawn NCT02696928 Phase 2 Artemeter-Lumefantrine and MB (combination therapy);Artemeter-Lumefantrine (combination therapy);Artemeter-Lumefantrine and Primaquine (combination therapy)
49 Phase 1 Study of the Safety and Immunogenicity of PpPfs25/ISA51 and ScPvs25/ISA51: Transmission Blocking Vaccines for Plasmodium Falciparum and Plasmodium Vivax Malaria Completed NCT00295581 Phase 1 PpPfs25/ISA51 & ScPvs25/ISA51
50 Development of a Safe and Reproducible Human Sporozoite Challenge Model for Plasmodium Vivax in Healthy Adults in the United States Completed NCT00935623 Phase 1

Search NIH Clinical Center for Plasmodium Vivax Malaria

Inferred drug relations via UMLS 71 / NDF-RT 50 :


halofantrine
Halofantrine hydrochloride
Mefloquine
Mefloquine Hydrochloride
Primaquine
Primaquine Phosphate

Cochrane evidence based reviews: malaria, vivax

Sources

Genetic Tests for Plasmodium Vivax Malaria

About this section
Sources

Anatomical Context for Plasmodium Vivax Malaria

About this section

Organs/tissues related to Plasmodium Vivax Malaria:

MalaCards : Spleen, Liver, T Cells, Bone Marrow, Myeloid, Kidney, Salivary Gland
Sources

Publications for Plasmodium Vivax Malaria

About this section

Articles related to Plasmodium Vivax Malaria:

(show top 50) (show all 2949)
# Title Authors PMID Year
1
The impact of phenotypic and genotypic G6PD deficiency on risk of plasmodium vivax infection: a case-control study amongst Afghan refugees in Pakistan. 53 62
20520804 2010
2
FY polymorphisms and vivax malaria in inhabitants of Amazonas State, Brazil. 53 62
20162434 2010
3
[Clinical and laboratorial alterations in Plasmodium vivax malaria patients and glucose-6-phosphate dehydrogenase deficiency treated with primaquine at 0.50 mg/kg/day]. 53 62
15330059 2004
4
Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. 53 62
12435700 2002
5
Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates. 53 62
11600366 2001
6
Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. 53 62
8036681 1994
7
The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis. 62
36472067 2022
8
Clinical-epidemiological characteristics and maternal-foetal outcomes in pregnant women hospitalised with COVID-19 in Venezuela: a retrospective study. 62
36471262 2022
9
Inhibition of a malaria host-pathogen interaction by a computationally designed inhibitor. 62
36367441 2022
10
Drug resistance of Plasmodium falciparum and Plasmodium vivax isolates in Indonesia. 62
36443817 2022
11
How does primaquine prevent Plasmodium vivax malarial recurrences? 62
36180306 2022
12
Transdermal Transmission Blocking Vaccine for Malaria using a Solid-in-Oil Dispersion. 62
36334812 2022
13
Molecular identification of vivax malaria relapse patients in the Yunnan Province based on homology analysis of the Plasmodium vivax circumsporozoite protein gene. 62
36334150 2022
14
Plasmodium vivax Relapse Rates in Allied Soldiers during the Second World War: Importance of Hypnozoite Burden. 62
36343595 2022
15
Longitudinal IgG antibody responses to Plasmodium vivax blood-stage antigens during and after acute vivax malaria in individuals living in the Brazilian Amazon. 62
36417454 2022
16
Is zoonotic Plasmodium vivax malaria an obstacle for disease elimination? 62
36397077 2022
17
Therapeutic efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium vivax malaria in Seacha area, Arbaminch Zuria District, South West Ethiopia. 62
36437454 2022
18
Elevated plasma α1-antichymotrypsin is a biomarker candidate for malaria patients. 62
36195566 2022
19
Plasmodium vivax in Children: Hidden Burden and Conspicuous Challenges, a Narrative Review. 62
36378465 2022
20
PvMSP-3α and PvMSP-3β genotyping reveals higher genetic diversity in Plasmodium vivax parasites from migrant workers than residents at the China-Myanmar border. 62
36403920 2022
21
Prolonged Breastfeeding and the Risk of Plasmodium vivax Infection and Clinical Malaria in Early Childhood: A Birth Cohort Study. 62
35763695 2022
22
Mimicking platelet indices in patients with malaria and dengue hemorrhagic fever: characteristics and clinical applications. 62
36221147 2022
23
Glucose 6 Phosphate Dehydrogenase (G6PD) quantitation using biosensors at the point of first contact: a mixed method study in Cambodia. 62
36195916 2022
24
Potential role of vaccines in elimination of Plasmodium vivax. 62
35489701 2022
25
Proteomic Analysis of Urine from Patients with Plasmodium vivax Malaria Unravels a Unique Plasmodium vivax Protein That Is Absent from Plasmodium falciparum. 62
36288055 2022
26
Impact of Environmental Modifications on the Ecology, Epidemiology, and Pathogenesis of Plasmodium falciparum and Plasmodium vivax Malaria in East Africa. 62
36228918 2022
27
Association between CYP2D6 phenotype and recurrence of Plasmodium vivax infection in south Korean patients. 62
36217154 2022
28
Asia-Pacific International Center of Excellence in Malaria Research: Maximizing Impact on Malaria Control Policy and Public Health in Cambodia and Papua New Guinea. 62
36228920 2022
29
Mass Spectrometry Identification of Biomarkers in Extracellular Vesicles From Plasmodium vivax Liver Hypnozoite Infections. 62
36030044 2022
30
Genetic Diversity of Circumsporozoite Surface Protein of Plasmodium vivax from the Central Highlands, Vietnam. 62
36297215 2022
31
Fighting Plasmodium chloroquine resistance with acetylenic chloroquine analogues. 62
36375339 2022
32
Enhancing Malaria Research, Surveillance, and Control in Endemic Areas of Kenya and Ethiopia. 62
36228905 2022
33
Epidemiology and clinical features of imported malaria: a 14-year retrospective single-centre descriptive study in Prague, Czech Republic. 62
36068598 2022
34
Polymorphism in the pvcrt-o and pvmdr-1 genes of Plasmodium vivax associated with a better prognosis for malaria. 62
36214439 2022
35
Increased circulating myeloid-derived suppressor cells in vivax malaria and severe falciparum malaria. 62
36068577 2022
36
IL-4, IL-10, CCL2 and TGF-β as potential biomarkers for severity in Plasmodium vivax malaria. 62
36178979 2022
37
Synergies between environmental degradation and climate variation on malaria re-emergence in southern Venezuela: a spatiotemporal modelling study. 62
36087604 2022
38
Spontaneous bilateral subdural hematoma in a patient with a prosthetic valve and association with plasmodium vivax malaria: A rare case report. 62
36045832 2022
39
Risk of hemolysis in Plasmodium vivax malaria patients receiving standard primaquine treatment in a population with high prevalence of G6PD deficiency. 62
35976559 2022
40
Vivax malaria in Duffy-negative patients shows invariably low asexual parasitaemia: implication towards malaria control in Ethiopia. 62
35915453 2022
41
African Plasmodium vivax malaria improbably rare or benign. 62
35667992 2022
42
CRISPR/Cas9 mediates efficient site-specific mutagenesis of the odorant receptor co-receptor (Orco) in the malaria vector Anopheles sinensis. 62
35484862 2022
43
An Evaluation of a New Quantitative Point-of Care Diagnostic to Measure Glucose-6-phosphate Dehydrogenase Activity. 62
36041490 2022
44
Spatiotemporal dynamics of malaria in Banmauk Township, Sagaing region of Northern Myanmar: characteristics, trends, and risk factors. 62
35902825 2022
45
Unreported mixed Plasmodium species infection may increase vivax malaria in India: a challenge for malaria elimination. 62
35088856 2022
46
Insights into Plasmodium vivax Asymptomatic Malaria Infections and Direct Skin-Feeding Assays to Assess Onward Malaria Transmission in the Amazon. 62
35895359 2022
47
Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria. 62
35857669 2022
48
Cost-Benefit Analysis of Tafenoquine for Radical Cure of Plasmodium vivax Malaria in Korea. 62
35818703 2022
49
Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria. 62
35857668 2022
50
Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria. Reply. 62
35857670 2022
Sources

Variations for Plasmodium Vivax Malaria

About this section
Sources

Expression for Plasmodium Vivax Malaria

About this section
Search GEO for disease gene expression data for Plasmodium Vivax Malaria.
Sources

Pathways for Plasmodium Vivax Malaria

About this section
Sources

GO Terms for Plasmodium Vivax Malaria

About this section

Biological processes related to Plasmodium Vivax Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to organic substance GO:0010033 9.33 TNF TFRC IL10
2 negative regulation of cytokine production involved in immune response GO:0002719 9.26 TNF IL10
3 chronic inflammatory response to antigenic stimulus GO:0002439 8.92 TNF IL10
Sources

Sources for Plasmodium Vivax Malaria

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....